Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G, Alumkal JJ, Higano CS, Chow Maneval E, Bandekar R, de Boer CJ, Yu MK, Rathkopf DE. Smith MR, et al. Among authors: bandekar r. Eur Urol. 2016 Dec;70(6):963-970. doi: 10.1016/j.eururo.2016.04.023. Epub 2016 May 6. Eur Urol. 2016. PMID: 27160947 Free PMC article. Clinical Trial.
Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.
Rathkopf DE, Smith MR, Ryan CJ, Berry WR, Shore ND, Liu G, Higano CS, Alumkal JJ, Hauke R, Tutrone RF, Saleh M, Chow Maneval E, Thomas S, Ricci DS, Yu MK, de Boer CJ, Trinh A, Kheoh T, Bandekar R, Scher HI, Antonarakis ES. Rathkopf DE, et al. Among authors: bandekar r. Ann Oncol. 2017 Sep 1;28(9):2264-2271. doi: 10.1093/annonc/mdx283. Ann Oncol. 2017. PMID: 28633425 Free PMC article. Clinical Trial.
Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone.
Rathkopf DE, Antonarakis ES, Shore ND, Tutrone RF, Alumkal JJ, Ryan CJ, Saleh M, Hauke RJ, Bandekar R, Maneval EC, de Boer CJ, Yu MK, Scher HI. Rathkopf DE, et al. Among authors: bandekar r. Clin Cancer Res. 2017 Jul 15;23(14):3544-3551. doi: 10.1158/1078-0432.CCR-16-2509. Epub 2017 Feb 17. Clin Cancer Res. 2017. PMID: 28213364 Free PMC article. Clinical Trial.
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).
Landgren CO, Chari A, Cohen YC, Spencer A, Voorhees P, Estell JA, Sandhu I, Jenner MW, Williams C, Cavo M, van de Donk NWCJ, Beksac M, Moreau P, Goldschmidt H, Kuppens S, Bandekar R, Clemens PL, Neff T, Heuck C, Qi M, Hofmeister CC. Landgren CO, et al. Among authors: bandekar r. Leukemia. 2020 Jul;34(7):1840-1852. doi: 10.1038/s41375-020-0718-z. Epub 2020 Feb 5. Leukemia. 2020. PMID: 32024950 Free PMC article. Clinical Trial.
Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
Fizazi K, De Bono JS, Flechon A, Heidenreich A, Voog E, Davis NB, Qi M, Bandekar R, Vermeulen JT, Cornfeld M, Hudes GR. Fizazi K, et al. Among authors: bandekar r. Eur J Cancer. 2012 Jan;48(1):85-93. doi: 10.1016/j.ejca.2011.10.014. Epub 2011 Nov 28. Eur J Cancer. 2012. PMID: 22129890 Clinical Trial.
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fosså A, Simpson D, Capra M, Liu T, Hsieh RK, Goh YT, Zhu J, Cho SG, Ren H, Cavet J, Bandekar R, Rothman M, Puchalski TA, Reddy M, van de Velde H, Vermeulen J, Casper C. van Rhee F, et al. Among authors: bandekar r. Lancet Oncol. 2014 Aug;15(9):966-74. doi: 10.1016/S1470-2045(14)70319-5. Epub 2014 Jul 17. Lancet Oncol. 2014. PMID: 25042199 Clinical Trial.
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma.
Brighton TA, Khot A, Harrison SJ, Ghez D, Weiss BM, Kirsch A, Magen H, Gironella M, Oriol A, Streetly M, Kranenburg B, Qin X, Bandekar R, Hu P, Guilfoyle M, Qi M, Nemat S, Goldschmidt H. Brighton TA, et al. Among authors: bandekar r. Clin Cancer Res. 2019 Jul 1;25(13):3772-3775. doi: 10.1158/1078-0432.CCR-18-3470. Epub 2019 Mar 19. Clin Cancer Res. 2019. PMID: 30890552 Clinical Trial.
Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease.
Casper C, Chaturvedi S, Munshi N, Wong R, Qi M, Schaffer M, Bandekar R, Hall B, van de Velde H, Vermeulen J, Reddy M, van Rhee F. Casper C, et al. Among authors: bandekar r. Clin Cancer Res. 2015 Oct 1;21(19):4294-304. doi: 10.1158/1078-0432.CCR-15-0134. Epub 2015 Jun 29. Clin Cancer Res. 2015. PMID: 26124203 Clinical Trial.
Dose selection of siltuximab for multicentric Castleman's disease.
Mayer CL, Xie L, Bandekar R, Qi M, van de Velde H, Reddy M, Qin X, Davis HM, Puchalski TA. Mayer CL, et al. Among authors: bandekar r. Cancer Chemother Pharmacol. 2015 May;75(5):1037-45. doi: 10.1007/s00280-015-2720-0. Epub 2015 Mar 18. Cancer Chemother Pharmacol. 2015. PMID: 25784388
27 results